Pharmacological trials of several hepcidin agonists have been developed in recent years as iron-restrictive therapies for PV, aiming to increase hepcidin levels, reduce iron and transferrin saturation, and inhibit erythropoiesis [30]. This evidence concerns the gene HAMP and acquired polycythemia vera.